Effect of gut microbiome alteration in inflammatory bowel disease
Microbiome-based therapy for irritable bowel syndrome
Keywords:
pre & probiotic, microbiome, inflammatory bowel syndromeAbstract
High morbidity rates are associated with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. New studies have suggested that dysbiosis may play a role in the etiology of inflammatory bowel disease, although the cause of IBD remains unknown. Several disease pathologies, such as inflammatory bowel disease, have been associated with the intestinal microbiota, a metabolic organ with multiple physiological functions. This review summarizes the present level of knowledge regarding the impact of altered gut microbiota in inflammatory bowel disease, the mechanisms by which this occurs, and the potential significance of therapeutic methods based on gut microbiota in the prevention and treatment of IBD. It has been demonstrated that directly targeting the intestinal microbiota can treat both inflammatory bowel disease and colitis in humans and animals. To characterize the core microbiome associated with IBD and the underlying pathophysiology, however, additional research employing well-designed randomized control trials and animal models is required, as there are currently insufficient data and contradictory results from previous studies. The environment will influence the probiotic and prebiotic treatment for IBD.
Downloads
References
Mulder DJ, Noble AJ, Justinich CJ, Duffin JM. A tale of two diseases: The history of inflammatory bowel disease. Journal of Crohn’s and Colitis. 2014;8(5):341-348. doi:https://doi.org/10.1016/j.crohns.2013.09.009
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nature Reviews Gastroenterology & Hepatology. 2015;12(12):720-727. doi:https://doi.org/10.1038/nrgastro.2015.150
Ouyang Q, Tandon R, Goh KL, et al. Management consensus of inflammatory bowel disease for the Asia?Pacific region. Journal of Gastroenterology and Hepatology. 2006;21(12):1772-1782. doi:https://doi.org/10.1111/j.1440-1746.2006.04674.x
de Souza HSP, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nature Reviews Gastroenterology & Hepatology. 2016;13(1):13-27. doi:https://doi.org/10.1038/nrgastro.2015.186
Rosen CE, Palm NW. Navigating the Microbiota Seas: Triangulation Finds a Way Forward. Cell Host & Microbe. 2018;23(1):1-3. doi:https://doi.org/10.1016/j.chom.2017.12.015
Gkouskou KK, Deligianni C, Tsatsanis C, Eliopoulos AG. The gut microbiota in mouse models of inflammatory bowel disease. Frontiers in Cellular and Infection Microbiology. 2014;4. doi:https://doi.org/10.3389/fcimb.2014.00028
Triantafillidis J. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Design, Development and Therapy. Published online April 2011:185. doi:https://doi.org/10.2147/dddt.s11290
Hoffmann C, Dollive S, Grunberg S, et al. Archaea and Fungi of the Human Gut Microbiome: Correlations with Diet and Bacterial Residents. Pan C, ed. PLoS ONE. 2013;8(6):e66019. doi:https://doi.org/10.1371/journal.pone.0066019
Koboziev I, Reinoso Webb C, Furr KL, Grisham MB. Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radical Biology and Medicine. 2014;68:122-133. doi:https://doi.org/10.1016/j.freeradbiomed.2013.11.008
Wu W, Chen F, Liu Z, Cong Y. Microbiota-specific Th17 Cells. Inflammatory Bowel Diseases. 2016;22(6):1473-1482. doi:https://doi.org/10.1097/mib.0000000000000775
Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451-455. doi:https://doi.org/10.1038/nature12726
Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, et al. The Key Role of Segmented Filamentous Bacteria in the Coordinated Maturation of Gut Helper T Cell Responses. Immunity. 2009;31(4):677-689. doi:https://doi.org/10.1016/j.immuni.2009.08.020
Qiu X, Zhang M, Yang X, Hong N, Yu C. Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. Journal of Crohn’s and Colitis. 2013;7(11):e558-e568. doi:https://doi.org/10.1016/j.crohns.2013.04.002
Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn’s disease and ulcerative colitis patients. Journal of Medical Microbiology. 2006;55(8):1141-1149. doi:https://doi.org/10.1099/jmm.0.46498-0
Rioux KP, Fedorak RN. Probiotics in the Treatment of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology. 2006;40(3):260-263. doi:https://doi.org/10.1097/00004836-200603000-00019
Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124(5):1202-1209. doi:https://doi.org/10.1016/s0016-5085(03)00171-9
Nell S, Suerbaum S, Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nature Reviews Microbiology. 2010;8(8):564-577. doi:https://doi.org/10.1038/nrmicro2403
Rossi M, Corradini C, Amaretti A, et al. Fermentation of Fructooligosaccharides and Inulin by Bifidobacteria: a Comparative Study of Pure and Fecal Cultures. Applied and Environmental Microbiology. 2005;71(10):6150-6158. doi:https://doi.org/10.1128/aem.71.10.6150-6158.2005
Rahimi R, Mozaffari S, Abdollahi M. On the Use of Herbal Medicines in Management of Inflammatory Bowel Diseases: A Systematic Review of Animal and Human Studies. Digestive Diseases and Sciences. 2008;54(3):471-480. doi:https://doi.org/10.1007/s10620-008-0368-x
Lukovac S, Belzer C, Pellis L, et al. Differential Modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of Host Peripheral Lipid Metabolism and Histone Acetylation in Mouse Gut Organoids. Onderdonk AB, ed. mBio. 2014;5(4). doi:https://doi.org/10.1128/mbio.01438-14
Foley MH, Cockburn DW, Koropatkin NM. The Sus operon: a model system for starch uptake by the human gut Bacteroidetes. Cellular and Molecular Life Sciences. 2016;73(14):2603-2617. doi:https://doi.org/10.1007/s00018-016-2242-x
Zou Y, Li WY, Wan Z, et al. Huangqin-Tang Ameliorates TNBS-Induced Colitis by Regulating Effector and Regulatory CD4+T Cells. BioMed Research International. 2015;2015:1-13. doi:https://doi.org/10.1155/2015/102021
Resta-Lenert S. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut. 2003;52(7):988-997. doi:https://doi.org/10.1136/gut.52.7.988
Lee JD, Rachmilewitz D, Raz E. Homeostatic Effects of TLR9 Signaling in Experimental Colitis. 2006;1072(1):351-355. doi:https://doi.org/10.1196/annals.1326.022
Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Alimentary Pharmacology & Therapeutics. 2004;20(10):1133-1141. doi:https://doi.org/10.1111/j.1365-2036.2004.02268.x
Roller M, Rechkemmer G, Watzl B. Prebiotic Inulin Enriched with Oligofructose in Combination with the Probiotics Lactobacillus rhamnosus and Bifidobacterium lactis Modulates Intestinal Immune Functions in Rats. The Journal of Nutrition. 2004;134(1):153-156. doi:https://doi.org/10.1093/jn/134.1.153
Damaskos D, Kolios G. Probiotics and prebiotics in inflammatory bowel disease: microflora “on the scope.” British Journal of Clinical Pharmacology. 2008;65(4):453-467. doi:https://doi.org/10.1111/j.1365-2125.2008.03096.x
van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. The New England journal of medicine. 2013;368(5):407-415. doi:https://doi.org/10.1056/NEJMoa1205037
Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2012;36(6):503-516. doi:https://doi.org/10.1111/j.1365-2036.2012.05220.x
Moayyedi P, Surette MG, Kim PT, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015;149(1):102-109.e6. doi:https://doi.org/10.1053/j.gastro.2015.04.001
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
